A useful way to understand Alpelisib is to start with the biology it targets. Inhibits the alpha isoform of PI3K, reducing downstream AKT signaling in PIK3CA-altered tumors. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. The database classifies it as Targeted Therapy; PI3K Inhibitor and associates it with Breast Cancer. Its principal oncology indications are HR-positive/HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after endocrine therapy; PIK3CA-related overgrowth spectrum in non-oncology indications. Depending on the disease, the agent may appear as a single-agent treatment, a component of combination therapy, or part of a defined treatment sequence. The documented regimen examples are Alpelisib + fulvestrant; alpelisib + endocrine therapy in selected breast cancer settings. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. This distinction matters because treatment selection is not determined simply by the presence of a cancer diagnosis; the tumor subtype, disease stage, previous therapy, and molecular or receptor characteristics can narrow the appropriate setting. The pharmacology helps explain its individual position among related medicines. Current labeling and the applicable oncology guideline should be consulted when the database is used for clinical reference.